AlzeCure Publishes its Interim Report for January - March 2024

STOCKHOLM, SWEDEN / ACCESSWIRE / April 25, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - March 2024 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/

"The first quarter of 2024 was positive and active for AlzeCure Pharma. In our clinical Alzheimer's program, NeuroRestore ACD856, we presented new preclinical data supporting neuroprotective and disease-modifying effects at the major international Alzheimer's conference AD/PD 2024. In addition, we had patents for NeuroRestore and ACD856 approved in China and several other countries, which strengthens our business development opportunities. During the quarter, we also selected a drug candidate in our pain project for treatment of knee osteoarthritis, TrkA-NAM. Our research and development was also further recognized by a government and ministerial visit, as well as by an investment by Eli Lilly's former global head of research and development, Dr. Jan Lundberg, who was also global head of research for AstraZeneca. He has also made himself available for a position on the company's Board of Directors, which is supported by the nomination committee. To finance the further development of the above-mentioned drug candidates, and to strengthen the company's financial position, the Board of Directors proposed during the quarter a rights issue of approximately SEK 52.8 million. It is both motivating and gratifying that the company is keeping up the pace as it continues to deliver new data that strengthen our position, and that we are receiving increasing recognition from external parties."

Martin Jönsson, CEO

Financial information for January - March, 2024
Figures in parentheses refer to the corresponding period of the previous year.

• Net sales during the period totaled SEK 0 thousand (0).
• Loss for the period totaled SEK -9,804 thousand (-9,545).
• Earnings per share, basic, totaled SEK -0.16 (-0.15).
• Cash flow from operating activities totaled SEK -10,063 thousand (28,095).
• Total assets at the end of the period amounted to SEK 22,688 thousand (57,974).
• Cash and cash equivalents at the end of the period totaled SEK 19,037 thousand (53,718).

Significant events during the period January - March, 2024